Mark Moasser, MD
Professor
Medicine
School of Medicine

415-353-7070

Physician-scientist seeking to understand the molecular basis of cancers, particularly oncogene-driven cancers, and to translate this knowledge into highly effective treatments for cancer.

Education & Training

Show all (4) Hide

Fellowship Medical Oncology Memorial Sloan-Kettering Cancer Center 1995
Residency Internal Medicine New York Hospital - Cornell Medical Center 1991
M.D. School of Medicine Tufts University 1988
B.A. Biophysics, Music University of Pennsylvania 1984

Websites

Show all (3) Hide

Clinical Profile at UCSF Medical Center (ucsfhealth.org)
BMS page (bms.ucsf.edu)
Moasser Lab (lab.moasser.com)

Grants and Projects

Show all (15) Hide

Understanding resistance in the HER2-HER3 tumor drive, NIH, 2006-2019
Development of first-in-class HER3 inhibitors, UCSF Clinical and Translational Sciences Institute Catalyst, 2017-2018
Model-based predictions of responses to RTK pathway therapies, National Institutes of Health, 2004-2015
Model-based predictions of responses to RTK pathway therapies, NIH/NCI, 2004-2015
A next-generation approach for inactivation of the HER2-HER3 tumor driver, BCRF-AACR, 2012-2014
Towards highly effective inactivation of HER2-HER3 signaling, California Breast Cancer Research Program, 2010-2014
Understanding the adaptational network underlying HER3 addiction, California Breast Cancer Research Program, 2012-2013
Breaking the HER3 barrier in the treatment of HER2-amplified breast cancer, Mary Kay Ash Charitable Foundation, 2009-2011
Anatomic and Biologic Staging of Breast Disease with MRI, NIH/NCI, 2006-2011
Adhesion signaling by a novel mitotic substrate of src, NIH, 2005-2011
An integrated approach towards the eradication of HER2-driven breast cancer, Susan G. Komen Foundation, 2008-2010
Pilot studies to develop probes for in vivo imaging of P13K/Akt pathway activity, NIH, 2007-2009
Promiscuous HER3 signaling; A new target in the treatment of breast cancer, Susan G. Komen Foundation, 2005-2008
HER3 infidelity and resistance to tyrosine kinase inhibitors, California Breast Cancer Research Program, 2005-2007
A novel mitotic phosphoprotein associated with src kinases, American Cancer Society, 2002-2006

Publications (90)

Top publication keywords:
src-Family KinasesCarcinogenesisReceptor, ErbB-2Molecular Targeted TherapyNeoplasmsBreast NeoplasmsAntigens, NeoplasmReceptor, ErbB-3Neoplasm ProteinsProtein Kinase InhibitorsQuinazolinesAntigens, CDAntineoplastic AgentsErbB ReceptorsCell Adhesion Molecules

A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
Breast cancer research and treatment 2023 Gumusay O, Huppert LA, Magbanua MJM, Wabl CA, Assefa M, Chien AJ, Melisko ME, Majure MC, Moasser M, Park J, Rugo HS
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Raghav KPS, Moasser MM
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.
Nature cancer 2023 Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Muñoz DP, Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg…
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.
Cell reports 2022 Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM
Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.
Cancer research 2022 Moasser MM

Show all (85 more) Hide

A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Cancer research communications 2022 Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN
Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
Blood advances 2022 Wu CH, Wang L, Yang CY, Wen KW, Hinds B, Gill R, McCormick F, Moasser M, Pincus L, Ai WZ
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.
Cell reports 2022 Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.
Cell reports 2022 Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid.
NPJ breast cancer 2021 Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, Moasser M, Magbanua M, Park JW, Rugo HS
Loss of CDCP1 triggers FAK activation in detached prostate cancer cells.
American journal of clinical and experimental urology 2021 Pollan SG, Teng PC, Jan YJ, Livingstone J, Huang C, Kim M, Mariscal J, Rodriguez M, Chen JF, You S, DiVizio D, Boutros PC, Chan KS, Rasorenova O, Cress A, Spassov D, Moasser M, Posadas EM, Freedland …
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.
Scientific reports 2021 Majumder A, Sandhu M, Banerji D, Steri V, Olshen A, Moasser MM
Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain.
Molecular cancer research : MCR 2021 Ruiz-Saenz A, Zahedi F, Peterson E, Yoo A, Dreyer CA, Spassov DS, Oses-Prieto J, Burlingame A, Moasser MM
Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.
Biochemical pharmacology 2020 Kazemi S, Kawaguchi S, Badr CE, Mattos DR, Ruiz-Saenz A, Serrill JD, Moasser MM, Dolan BP, Paavilainen VO, Oishi S, McPhail KL, Ishmael JE
Expression and purification of active human kinases using Pichia pastoris as a general-purpose host.
Protein expression and purification 2020 Abdel Aziz MH, Fan Y, Liu L, Moasser MM, Fu H, Jura N, Arkin MR
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
Nature communications 2020 Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
The Journal of investigative dermatology 2020 Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ
HER family in cancer progression: From discovery to 2020 and beyond.
Advances in cancer research 2020 Kumar R, George B, Campbell MR, Verma N, Paul AM, Melo-Alvim C, Ribeiro L, Pillai MR, da Costa LM, Moasser MM
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.
Nature cell biology 2019 Coppé JP, Mori M, Pan B, Yau C, Wolf DM, Ruiz-Saenz A, Brunen D, Prahallad A, Cornelissen-Steijger P, Kemper K, Posch C, Wang C, Dreyer CA, Krijgsman O, Lee PRE, Chen Z, Peeper DS, Moasser MM, …
A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src.
Cell reports 2018 Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM
HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
Cancer research 2018 Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM
Regulation of inside-out β1-integrin activation by CDCP1.
Oncogene 2018 Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, Knudsen BS
Targeting HER2 by Combination Therapies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Ruiz-Saenz A, Moasser MM
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN
CD318 is a ligand for CD6.
Proceedings of the National Academy of Sciences of the United States of America 2017 Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F
Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase.
Cell chemical biology 2017 Littlefield P, Moasser MM, Jura N
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
Breast cancer research and treatment 2016 Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN
Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.
Breast cancer research and treatment 2016 Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Oncotarget 2015 Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM
The Evolving Landscape of HER2 Targeting in Breast Cancer.
JAMA oncology 2015 Moasser MM, Krop IE
A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.
Molecular cancer therapeutics 2015 Amin DN, Ahuja D, Yaswen P, Moasser MM
Disentangling multidimensional spatio-temporal data into their common and aberrant responses.
PloS one 2015 Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ
Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.
Oncogene 2015 Ruiz-Saenz A, Sandhu M, Carrasco Y, Maglathlin RL, Taunton J, Moasser MM
HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive.
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Campbell MR, Moasser MM
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, …
A multilevel model of postmenopausal breast cancer incidence.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2014 Hiatt RA, Porco TC, Liu F, Balke K, Balmain A, Barlow J, Braithwaite D, Diez-Roux AV, Kushi LH, Moasser MM, Werb Z, Windham GC, Rehkopf DH
Two dimensions in targeting HER2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Moasser MM
Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM
RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.
Chemistry & biology 2014 Littlefield P, Moasser MM, Jura N
Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells.
Cancer research 2012 Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM
HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.
The Biochemical journal 2012 Amin DN, Sergina N, Lim L, Goga A, Moasser MM
A tumor-suppressing function in the epithelial adhesion protein Trask.
Oncogene 2011 Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
British journal of cancer 2011 Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE
The structural features of Trask that mediate its anti-adhesive functions.
PloS one 2011 Spassov DS, Ahuja D, Wong CH, Moasser MM
Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state.
Cell cycle (Georgetown, Tex.) 2011 Spassov DS, Wong CH, Moasser MM
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, …
Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling.
Molecular and cellular biology 2010 Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.
Seminars in cell & developmental biology 2010 Amin DN, Campbell MR, Moasser MM
HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Campbell MR, Amin D, Moasser MM
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
Science translational medicine 2010 Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM
MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.
Journal of magnetic resonance imaging : JMRI 2009 Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM
The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.
The American journal of pathology 2009 Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM
Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton…
HER-2-directed, small-molecule antagonists.
Current opinion in investigational drugs (London, England : 2000) 2008 Arkin M, Moasser MM
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
The Biochemical journal 2008 Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D
The epidermal growth factor receptor family: biology driving targeted therapeutics.
Cellular and molecular life sciences : CMLS 2008 Wieduwilt MJ, Moasser MM
Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.
Seminars in oncology 2008 Chien AJ, Moasser MM
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Journal of magnetic resonance imaging : JMRI 2007 Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM
The HER family and cancer: emerging molecular mechanisms and therapeutic targets.
Trends in molecular medicine 2007 Sergina NV, Moasser MM
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Breast cancer research and treatment 2007 Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN
Targeting HER proteins in cancer therapy and the role of the non-target HER3.
British journal of cancer 2007 Hsieh AC, Moasser MM
Targeting the function of the HER2 oncogene in human cancer therapeutics.
Oncogene 2007 Moasser MM
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.
Oncogene 2007 Moasser MM
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Nature 2007 Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy.
Journal of the American Geriatrics Society 2006 Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.
Journal of the American Geriatrics Society 2006 Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.
Breast cancer research and treatment 2006 Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C
Adhesion signaling by a novel mitotic substrate of src kinases.
Oncogene 2005 Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Clinical breast cancer 2005 Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Breast cancer research and treatment 2005 Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA
S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors.
Cell cycle (Georgetown, Tex.) 2004 Mizenina OA, Moasser MM
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 She QB, Solit D, Basso A, Moasser MM
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM
The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
Breast cancer research and treatment 2002 Moasser MM, Rosen N
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, …
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
Cancer research 2001 Münster PN, Srethapakdi M, Moasser MM, Rosen N
Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.
Prostate cancer and prostatic diseases 2001 Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Cancer research 1999 Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.
Proceedings of the National Academy of Sciences of the United States of America 1998 Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N
Derivation and characterization of retinoid-resistant human embryonal carcinoma cells.
Differentiation; research in biological diversity 1996 Moasser MM, Khoo KS, Maerz WJ, Zelenetz A, Dmitrovsky E
Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line.
International journal of cancer 1996 Baldassarre G, Bianco C, Tortora G, Ruggiero A, Moasser M, Dmitrovsky E, Bianco AR, Ciardiello F
Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors.
Oncogene 1995 Ahn MJ, Langenfeld J, Moasser MM, Rusch V, Dmitrovsky E
all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial.
Cancer 1995 Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ, Dmitrovsky E
Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
Oncogene 1995 Ahn MJ, Nason-Burchenal K, Moasser MM, Dmitrovsky E
Overexpression of the retinoic acid receptor gamma directly induces terminal differentiation of human embryonal carcinoma cells.
Oncogene 1995 Moasser MM, Reuter VE, Dmitrovsky E
Response and resistance to retinoic acid are mediated through the retinoic acid nuclear receptor gamma in human teratocarcinomas.
Oncogene 1994 Moasser MM, DeBlasio A, Dmitrovsky E

Mark Moasser, MDProfessorMedicineSchool of Medicine